Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Henia Dar, Daniel Henderson, Zinkal Padalia, Ashley Porras, Dakai Mu, Maeng Kyungah, Seshidhar Police, Demetrios Kalaitzidis, Jonathan Terrett, Jason Sagert
Title Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma
Journal Vol Issue Date Pages Journal Short Title
URL https://ashpublications.org/blood/article/132/Supplement%201/1921/261777/Preclinical-Development-of-CTX120-an-Allogeneic
Abstract Text Blood (2018) 132 (Supplement 1): 1921

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
CTX120 CTX120 0 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
CTX120 CTX-120|CTX 120 CTX120 consists of allogeneic T-lymphocytes engineered with CRISPR/Cas9 to insert a BCMA-targeting chimeric antigen receptor (CAR) in the T-cell receptor alpha constant (TRAC) locus, and to simultaneously remove the endogenous T cell receptor (TCR) and MHC class I, which potentially results in increased cytotoxicity against BCMA-expressing tumor cells, and inhibits tumor growth (Blood (2018) 132 (Supplement 1): 1921).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References